Tag Archives: Value Based Pricing

Fair and Affordable Access to Medicines in the NHS (NHS England / UCL IIPP)

Posted on October 19, 2018 by Dementia and Elderly Care News

Summary Adalimumab is a medicine on which hospitals spend more than £400 million a year. The patent has now expired, allowing patients to be treated with a cheaper biosimilar, saving around £150 million per year (which can be re-directed to … Continue reading →

Posted in Acute Hospitals, Commissioning, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, National, NHS, NHS England, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Access to Medicines, Adalimumab, Added Benefit of New Drugs (Analysis), Affordability, Affordability (Facilitators of Innovation), Affordability and Access to Essential Medicines, Affordable Medicines, Alignment of Corporate Interests With the Public Interest, Alternative Health Innovation Model (Proposals), Andrew Davies: Director of Hospital Pharmacy at NHS Improvement, Association of the British Pharmaceutical Industry (ABPI), Barriers to Collaboration and Knowledge Sharing, Barriers to Innovation, Barriers to Innovation: Dominance of Vested Interests, Better Procurement, BioCubaFarma, Biological Medicines and Biosimilars, Biosimilars for Adalimumab, Cancer Innovation Fund (CIF), Charging Prices the Market Will Bear, Collaboration and Transparency, Compulsory Licensing, Compulsory or Public Non-Commercial Use Licences, Decline of Drugs Research and Development Efficiency, Defense Advanced Research Projects Agency (Darpa), Delinkage, Delinkage of Incentives for Innovation From High Prices, Directed Innovation, Direction of Innovation for Public Value, Drug Patent Monopolies: Negation of Competition, Drug Patents, Drug Pricing Negotiations, Drug Pricing Strategies, Drugs for Neglected Diseases initiative (DNDi), Effective Knowledge Sharing, Energiewende in Germany, European Public Health Alliance, Expensive Drugs, Finance and Budgeting: Affordability (Barriers to Innovation), Finance and Procurement, Global Justice Now, Health Advanced Research Projects Agency (HARPA), Health Innovation, Health Innovation Better Managed to Deliver Public Value, Heidi Chow: Global Justice Now, High Medication Prices Placing Pressure on NHS Budgets and Causing Rationing, High Prices Failing to Reflect Social Value, Highly-Priced Medicines, Human Genome Project (HGP), I-MAK, Improving Access to Medicines, Incentivising Investment in Innovation, Inefficiencies in Innovation, Innogen, Innovation and Improvement, Innovation Direction, Intellectual Property Rights (IPR) Geared to Encouraging Innovation, Intellectual Property Rights (IPR) Geared to Public Value, Intellectual Property Rules Geared for Public Health, International Nonproprietary Names (INN), Just Treatment, Knowledge Ecology International, Knowledge Governance, Lack of Safeguards in Current Pharma R&D Model, Lack of Transparency and Public Accountability, Lack of Transparency and Stifled Collaboration, Learning from DARPA, Mariana Mazzucato: UCL Institute for Innovation and Public Purpose, Me-Too Drugs, Medicines Patent Pool (MPP), Medicines Price Transparency, Mission-Driven Innovation, Mission-Oriented Innovation Policy, Mission-Oriented Thinking, Monopoly Pricing, Open Society Foundations, Opportunities for Volume-Based and Pooled Procurement, Out-of-Reach Drug Prices, Patent Monopolies Negating Competition, Patentability Criteria Consistent With TRIPS Agreement, Patents Blocking Learning Diffusion and Collaboration, People’s Prescription: Re-Imagining Health Innovation to Deliver Public Value, Pharmaceutical Price Regulation Scheme (PPRS), Pooled Procurement Mechanism, Pricing Legislation, Principles of Health Innovation Model Designed For Public Value, Procurement, Profit Maximisation Versus Public Value Maximisation, Public Investment in Biomedical Innovation, Public Purpose, Public Purpose and Public Value, Public Value, Public Value Maximisation, Reducing Spending on Expensive Drugs, Reducing Waste in the NHS, Saoirse Fitzpatrick: STOPAIDS, Short-Termism and Financialisation, Simon Stevens: Chief Executive of NHS England, Smart Procurement, Social Value, STOPAIDS, Thinking Like a Patient and Acting Like a Taxpayer, Trade Related Aspects of Intellectual Property Rights (TRIPS), TRIPS Agreement, TRIPs-Plus Provisions, Upstream Investment in Research and Development Negotiated Into Better Downstream Public Benefit, US Biochemical Advanced Research and Development Authority (BARDA), US Department of Health: Health Advanced Research Projects Agency (HARPA), Value Based Pricing, Value-Based Pricing (Imperfect Model), Value-Based Pricing: Corrupted Into Maximising Value Extraction (Versus Public Good), Variations in Procurement, Voluntary Scheme for Branded Medicines Pricing and Access, World Intellectual Property Organisation (WIPO) | Leave a comment

Tag Archives: Value Based Pricing

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites